Treatment implications of a delayed diagnosis of maturity‐onset diabetes of the young

Maturity-onset diabetes of the young (MODY) is a rare form monogeneic that classically presents as non-insulin requiring with evidence autosomal dominant inheritance in individuals who are typically and lean. However, these criteria do not capture all cases can also overlap other types diabetes. The hepatocyte nuclear factor-1 alpha (HNF1A) mutation common cause MODY highly sensitive to sulphonylureas, which should be first-line therapy. Our case represents diagnostic challenges HNF1A implications delayed diagnosis, lead reduced success sulphonylurea treatment.